Early administration of small-molecule glycoprotein IIb/IIIa inhibitors before primary percutaneous coronary intervention for st-elevation myocardial infarction: Insights from randomized clinical trials

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 15, Issue 2, 2010, Pages 135-144

  Dong, Lili ^a   Zhang, Feng ^a   Shu, Xianhong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Abciximab; Eptifibatide; Glycoprotein IIb IIIa inhibitor; Myocardial infarction; Percutaneous coronary intervention; Tirofiban

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; RAPAMYCIN; TIROFIBAN;

ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MEGADOSE; DRUG SAFETY; EARLY INTERVENTION; HEART MUSCLE PERFUSION; HEART REINFARCTION; HUMAN; META ANALYSIS; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TYROSINE;

EID: 77951901398     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248409359913     Document Type: Article

References (38)

1. Van de Werf F., Bax J., Betriu A., et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008 ; 29 (3). 2909-2945.
2. Canadian Cardiovascular Society, American Academy of Family Physicians, American College of Cardiology, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2008 ; 51 (2). 210-247.
3. vang?t Hof AW, Liem A., Suryapranata H., et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Circulation. 1998 ; 97 (23). 2302-2306. (Pubitemid 28280383)
4. De Luca G., vang?t Hof AW, Ottervanger JP, et al. Ageing, impaired myocardial perfusion, and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Eur Heart J. 2005 ; 26 (7). 662-666. (Pubitemid 40516877)
5. Petronio AS, Rovai D., Musumeci G., et al. Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty. Eur Heart J. 2003 ; 24 (1). 67-76.
6. Montalescot G., Barragan P., Wittenberg O., et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001 ; 344 (25). 1895-1903. (Pubitemid 32553358)
7. Antoniucci D., Migliorini A., Parodi G., et al. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone. Circulation. 2004 ; 109 (4). 1704-1706.
8. De Luca G., Suryapranata H., Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA. 2005 ; 293 (14). 1759-1765.
9. Montalescot G., Antoniucci D., Kastrati A., et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: A European meta-analysis on individual patientsg? data with long-term follow-up. Eur Heart J. 2007 ; 28 (4). 443-449.
10. De Luca G., Gibson CM, Bellandi F., et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis. Heart. 2008 ; 94 (12). 1548-1558.
11. Zeymer U. EVA-AMI Trial (Eptifibatide versus Abciximab in primary PCI for acute ST elevation myocardial infarction). Presented at AHA 2007 in Orlando, USA on November 4, 2007. http://www.cardiosource.com/img/Zeymer-Slides.ppt. Accessed April 30, 2009.
12. Valgimigli M., Campo G., Percoco G., et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA. 2008 ; 299 (15). 1788-1799.
13. Marzocchi A., Manari A., Piovaccari G., et al. Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trial. Eur Heart J. 2008 ; 29 (24). 2972-2980.
14. Egger M., Ebrahim S., Smith GD Where now for meta-analysis ? Int J Epidemiol. 2002 ; 31 (1). 1-5.
15. Valgimigli M., Percoco G., Malagutti P., et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA. 2005 ; 293 (17). 2109-2117.
16. van Werkum JW, Gerritsen WB, Kelder JC, et al. Inhibition of platelet function by abciximab or high-dose tirofiban in patients with STEMI undergoing primary PCI: a randomised trial. Neth Heart J. 2007 ; 15 (11). 375-381.
17. Danzi GB, Sesana M., Capuano C., Mauri L., Berra Centurini P., Baglini R. Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function. Am J Cardiol. 2004 ; 94 (1). 35-39.
18. Ernst NM, Suryapranata H., Miedema K., et al. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 ; 44 (6). 1187-1193.
19. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial: phase I findings. N Engl J Med. 1985 ; 312 (14). 932-936.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG Measuring inconsistency in meta-analyses. BMJ. 2003 ; 327 (7414). 557-560.
21. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959 ; 22 (4). 719-748.
22. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 ; 7 (3). 177-188.
23. Phillips DR, Charo IF, Scarborough RM GP IIb/IIIa. The responsive integrin. Cell. 1991 ; 65 (3). 359-362.
24. Quinn M., Deering A., Stewart M., Cox D., Foley B., Fitzgerald D. Quantifying GP IIb/IIIa receptor binding using 2 monoclonal antibodies. Discriminating abciximab and small molecular weight antagonists. Circulation. 1999 ; 99 (17). 2231-2238.
25. Topol EJ, Byzova TV, Plow EF Platelet GPIIb-IIIa blockers. Lancet. 1999 ; 353 (9148). 227-231.
26. Martínez-Ríos MA, Rosas M., González H., et al. Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction. Am J Cardiol. 2004 ; 93 (3). 280-287.
27. Zeymer U., Zahn R., Schiele R., et al. Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial. Eur Heart J. 2005 ; 26 (19). 1971-1977.
28. Shen J., Zhang Q., Zhang RY, et al. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Coron Artery Dis. 2008 ; 19 (4). 271-277.
29. Vang?t Hof AW, Ten Berg J., Heestermans T., et al, and the Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet. 2008 ; 372 (9638). 537-546.
30. Stone GW, Cox D., Garcia E., et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation. 2001 ; 104 (6). 636-641.
31. The GUSTO investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med. 1993 ; 329 (22). 1615-1622.
32. Schroder R., Dissmann R., Bruggemann T., et al. Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol. 1994 ; 24 (2). 384-391.
33. de Lemos JA, Braunwald E. ST segment resolution as a tool for assessing the efficacy of reperfusion therapy. J Am Coll Cardiol. 2001 ; 38 (5). 1283-1294.
34. vang?t Hof AW, Liem A., de Boer MJ, Zijlstra F. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Lancet. 1997 ; 350 (9078). 615-619.
35. Claeys MJ, Bosmans J., Veenstra L., Jorens P., De RaedtH, Vrints CJ Determinants and prognostic implications of persistent ST-segment elevation after primary angioplasty for acute myocardial infarction: importance of microvascular reperfusion injury on clinical outcome. Circulation. 1999 ; 99 (15). 1972-1977.
36. Vorobcsuk A., Kónyi A., Aradi D., et al. Transradial versus trans-femoral percutaneous coronary intervention in acute myocardial infarction Systematic overview and meta-analysis. Am Heart J. 2009; 158 (5). 814-821.
37. Lee CH, Tan E., Wong HB, Tay E., Tan HC Impact of different Asian ethnic groups on correlation between heparin dose, activated clotting time and complications in percutaneous coronary intervention. Int J Cardiol. 2008 ; 130 (3). 500-502.
38. Gallo R., Steinhubl SR, White HD, et al. Impact of anticoagulation regimens on sheath management and bleeding in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial. Catheter Cardiovasc Interv. 2009 ; 73 (3). 319-325.